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Inflammation is a defense mechanism designed to eliminate microorganisms, 
among other agents, to protect living tissues from infections, injuries, and to enhance 
tissue repair mechanisms. Non-steroidal anti-inflammatory drugs and synthetic 
glucocorticoids are widely used, but unfortunately, they have been associated with 
many side effects, namely the increased risk of upper gastrointestinal complications. 
 Therefore, the discovery of new, efficient, and safer anti-inflammatory agents is 
crucial to prevent and treat inflammatory processes. Natural matrices, such as tubers, 
have been explored and described as having a huge diversity of bioactive molecules 
with anti-inflammatory capacity and with few undesirable effects. Thus, in the present 
work, the hydroethanolic extracts of two tubers, Zingiber officinale Roscoe (Ginger) 
and Bryonia dioica Jacq. Were studied as potential anti-inflammatory agents.  
The main objective of this work was to validate the anti-inflammatory activity of 
these tubers through two anti-inflammatory assays in vitro: i) inhibition of the 
production of nitric oxide (NO) in a cell model, RAW 264.7 - stimulated rat 
macrophage cell line by lipopolysaccharide (LPS); ii) inhibition of the activity of the 
inducible nitric oxide synthase (iNOS) enzyme. To ensure the safe use of these 
extracts, cytotoxic activity in tumor and non-tumor lines and cellular antioxidant 
activity were evaluated. Cell cycle analysis and apoptosis were also assessed using 
flow cytometry techniques. In addition, these extracts were characterized in terms of 
organic acids and phenolic compounds through chromatographic techniques to 
establish a structure-activity relationship.  
According to the results obtained, the two tubers revealed the presence of 
organic acids, well described bioactive molecules, and four phenolic compounds were 
also identified in Z. officinale. Both samples are promising anti-inflammatory agents, 
since they exhibited the ability to inhibit NO production with very low IC50 values. It 
should be noted that B. dioica showed an anti-inflammatory and cytotoxic activity 
more effective than the standards used. The results of antioxidant activity were less 
promising, as both samples were less effective than quercetin. The results of the cell 
cycle show that B. dioica suppresses the G0/G1 phase, while apoptotic analysis 
indicates that Z. officinale has a greater capacity to induce cell death by the apoptotic 




potential of these tubers, however further tests are needed to evaluate other 







A inflamação é um mecanismo de defesa concebido para eliminar 
microrganismos,entreoutros agentes, para proteger os tecidos vivos de infeções, 
lesões, e para potenciar os mecanismos de reparação tecidular. Os anti-inflamatórios 
não esteroides e glucocorticoidessintéticos são muito utilizados, mas infelizmente têm 
sido associados a muitos efeitos secundários, nomeadamenteao risco acrescido de 
complicações gastrointestinais superiores. Portanto, a descoberta de agentes anti-
inflamatórios novos, eficientes e mais seguros é crucial para prevenir e tratar 
processos inflamatórios. As matrizes naturais, como os tubérculos, têm sido 
exploradas e descritas como detentores de uma enorme diversidade de moléculas 
bioativas com capacidade anti-inflamatória e com poucos efeitos indesejáveis. Assim, 
no presente trabalho, os extractoshidroetanólicos de dois tubérculos, Zingiber 
officinale Roscoe (Ginger) e Bryonia dioica Jacq. foram estudadoscomo potenciais 
agentes anti-inflamatórios. O principal objetivo deste trabalho foi a validação da 
atividade anti-inflamatória destes tubérculos através de dois ensaios anti-inflamatórios 
in vitro: i) inibição da produção de óxido nítrico (NO) num modelo celular,RAW 
264.7–linhacelularde macrófagos deratoestimulado por lipopolissacarídeo (LPS); ii) 
inibição da atividade da enzima óxido nítrico sintaseindutível (iNOS). Para garantir a 
segurança da utilização dos referidos extratos foi avaliada a atividade citotóxica em 
linha tumorais e não tumorais e a atividade antioxidante celular. A análise do ciclo 
celular e a apoptose também foram avaliadas usando técnicas decitometria de fluxo. 
Além disso, estes extratosforam também caracterizados em termos de ácidos orgânicos 
e compostos fenólicos através de técnicas cromatográficas a fim de estabelecer uma 
relação estrutura-atividade. De acordo com os resultados obtidos, ambas as amostras 
revelaram a presença de ácidos orgânicos, moléculas de reconhecida bioatividade, 
tendo sido ainda detetados 4 compostos fenólicos na amostra Z. officinale. Os dois 
tubérculos são agentes anti-inflamatórios promissores, já que exibiram capacidade 
para inibir a produção de NO com valores muito baixos de IC50. De salientar que a 
B.dioica mostrou uma atividade anti-inflamatória e citotóxica mais eficaz do que os 
padrões utilizados. Os resultados daatividade antioxidante foram menos promissores, 
já que ambas as amostras foram menos eficazes do que a quercetina. Os resultados do 
ciclo celular mostram que a B.dioica suprime a fase G0/G1, enquanto a análise 




celular pela via apoptótica. Estes resultados são muito promissores e realçam o 
potencial anti-inflamatório destes tubérculos, no entanto é necessário fazer mais 






Inflammation is a defense mechanism  that is designed to eradicate microbes or 
irritants to protect living tissues from infection, injuries, and to potentiate tissue repair. 
This process leads to changes in blood flow, an increase in permeability of blood 
vessels, and the migration of fluid, proteins, and white blood cell (leukocytes) from the 
circulation system to the site of the damaged tissue. If the inflammatory response last 
for few days it is called acute inflammation however if it last for longer time it is 




 The inflammation process is characterized by five major stages: i) rubor 
(redness, due to hyperemia); tumor (swelling caused by increased permeability of the 
microvasculature and leakage of protein into the interstitial space); ii) calor (heat 
associated with the increased blood flow and the metabolic activity of the cellular 
mediators of inflammation);  iii) dolor (pain, in part due to changes in the peri-




The common anti-inflammatory drugs can calm the symptoms or limit the 
deleterious effects of inflammation in the organism. Usually, there are two types of 
anti-inflammatory drugs, the non-steroidal and glucocorticoids. These drugs can be 
applied in different forms, namely by oral treatment, suppository, inhalation, infusion 
or local by ointment, eye drops among others); however these anti-inflammatory drugs 
have serious side effects
3
. The use of oral steroids, aspirin and acetaminophen at doses 
of approximately 2 g each is associated with a double increase in the risk of upper 
gastrointestinal complications; non-steroidal anti-inflammatory drugs are associated 
with a nearly fourfold increase in risk 
3
. 
 Therefore, it is crucial to find new and efficient anti-inflammatory drugs that 
can eliminate the infection without undesired side effects. Natural products have been 
explored and described as possessing a huge diversity of bioactive molecules with 
anti-inflammatory capacity 
4
. Thus, in this study we are going to evaluate the 
bioactivities of B. dioica and Z. officinale as promising anti-inflammatory agent susing 
the hydro-ethanolic extract. 
Beside the anti-inflammatory activity, we are going to test the cytotoxicity, NOS 




and the organic composition to understand better the mechanisms of action of both 
samples as anti-inflammatory agents. 
1.1. Inflammatory mechanisms 
1.1.1. Initiation of the inflammatory response 
1.1.1.1 Vasodilatation, fluid exudation and leukocyte migration 
Vasodilatation is a typical characteristic of acute inflammation, which is 
clinically characterized at the injury site by redness which warmth. The vasodilatory 
response aims at promoting the local delivery of soluble mediators and inflammatory 
cells. Inflammation-induced vasodilatation is mainly mediated by vasodilating 
prostaglandins and NO. Upon exposure to microbial products or pro-inflammatory 
cytokines, the activated leukocytes develop inducible NOS (iNOS).   The NO provided 
by cyclic GMP-dependent mechanisms induces subsequent smooth muscle relaxation.  
Prostacycline (PGI2), PGD2, PGE2 and PGF2a are the main vasodilatory 
prostaglandins (Figure1) 
1




Vasodilatation caused by inflammation first requires arterioles accompanied by 
the formation of new micro-vascular beds. Widespread vasodilatation can induce 
systemic hypotension and shock in cases of severe systemic inflammation such as 
sepsis.   Such physiological modifications are potentiated by myocardial depression 
caused by the sepsis stage, a disease triggered by the activities of NO and pro-















Figure 1: The production of vasodilatory prostaglandins through the actions of 
phospholipase and cyclooxygenase. The major vasodilatory prostaglandins are 





At the same time, capillary hydrostatic pressure at the injury site is increased 
early during inflammation or damage triggered by local vasodilatation.  Outpouring of 
protein-rich fluid induces erythrocyte aggregation in small vessels and increase blood 
viscosity.  This flow of trans-vascular fluid gradually returns to normal intravascular 




The increase in vascular permeability, the temporary rise in capillary hydrostatic 
pressure and the decrease in plasma oncotic pressure work together to induce a trans-
vascular fluid and protein flow into the inflamed interstitium.  The role of these 
alterations is to facilitate the delivery to the injury site of soluble factors such as 
antibodies and acute-phase proteins.  However, extreme systemic inflammation can 
cause excessive increases in vascular permeability, which can contribute to the 
development of oedema in the lungs and extremities.  In critically ill patients, the 
accumulation of fluid in the lungs causes the acute respiratory distress syndrome, a 
significant source of morbidity and death 
7
. 
Leukocyte margination, adhesion, and migration are followed by vasodilatation 
and fluid exudation. Neutrophils are the first and most numerous leukocytes to appear 
in an infection or inflammatory site. The process of neutrophil movement from 
intravascular space into the inflamed interstitium occurs mainly in the systemic 
circulation of postcapillary venules and in the lung's pulmonary capillaries. The 





margination, spinning, adhesion, diapedesis and chemotaxis 
8
 (Figure 2).The process 
of neutrophil migration from the main bloodstream to the vessel's periphery is 
denomited marginalisation. Stasis after fluid exudation at the site of inflammation and 
physical contact between erythrocytes and neutrophils facilitates this process. A poor 
adhesive association occurs after margination between neutrophils and endothelial 
vascular cells, allowing neutrophils to linger in close proximity to the vascular 
endothelium. Neutrophil rolling is encouraged by the shear stress of moving 
erythrocytes, the rolling speed being proportional to the velocity of red cells 
9
. 
These interactions are mediated by selectins and their ligands, promoting rolling 
of the neutrophils. The adherence to neutrophils is then potentiated by interactions 
with beta-integrins and intercellular adhesion molecules (ICAM). Neutrophils then 
move by contact with chemoattractant molecules such as chemokines and bacterial 





Figure 2: Neutrophil rolling processes, adhesion system, diapedesis and 
chemotaxis.The formation of loose connections between endothelial cells and 
neutrophils is caused by inflammation, which produces neutrophil margination. 
Selectins and their ligands moderate these connections, allowing neutrophils to roll 
more easily. Interactions between beta-integrins and  ICAM  then enhance neutrophil 
adherence. After interacting with chemoattractant molecules such chemokines and 










1.1.1.2 Activation of the coagulation cascade during inflammation 
Inflammation is closely associated with coagulation. The cascade of coagulation 
occurs after skin damage and during an infection process. It is divided into two 
pathways which converge and ultimately cause thrombin activation with the 
subsequent fibrinogen cleavage into fibrin (Figure 3). The intrinsic pathway is a 
sequence of plasma proteins regulated by Hageman factor (factor XII), a synthesized 
protein in the liver that is regulated by binding to collagen, basement membrane or 
activated platelets 
11
. Enabled Hageman factor activates a cascade of proteins to start 
resulting in thrombin production. Guided tissue pain most commonly stimulates the 
intrinsic pathway. 
The extrinsic pathway, by comparison, is triggered by the development of factor 
tissue. Recent studies suggest that the extrinsic pathway is the primary coagulation 
pathway that is triggered during infection and systemic inflammation, particularly 
during sepsis and the systemic inflammatory response syndrome 
12
.Tissue factor is 
exerted on surfaces of tissues that are not usually exposed to the vascular 
compartment, such as subcutaneous tissues and blood vessel adventitial layers. In 
addition, endothelial cells and activated monocytes develop tissue factor in response to 
TNF-a, IL-1, IL-6 and C-reactive protein during cycles of inflammation 
13
 . The 
presence of tissue factor triggers the activation of factor VII, which then forms a 
complex with tissue factor and eventually induces the production of thrombin by 





Figure 3 : The coagulation cascade. The extrinsic and intrinsic coagulation pathways 
combine to form a final common pathway. Tissue factor, which is released in response 
to tissue damage and macrophage activity, activates the extrinsic pathway. The intrinsic 
pathways are activated when sub-endothelial collagen and activated platelets are 




Coagulation cascade activation is not only important for the development of 
fibrin clots but it also has major effects on the pro-inflammatory response. Pro-
inflammatory activity has been shown to be caused by factor Xa, thrombin, and tissue 
factor – VIIa complex In particular, thrombin and the tissue factor – VIIa complex that 
induce mononuclear and endothelial cells to produce pro-inflammatory cytokines such 
as TNF-
14
. This influence tends to be mediated by binding certain factors on the 
surface of target cells to protease-activated receptors. Acute inflammation then allows 
the coagulation cascade to start, which can then potentiate the inflammatory response 
further. 
 
1.1.2. Complement system 
The complement system is a collection of microbial-activated proteins that help 
to facilitate inflammation and microbial degradation. The nutrient cascade is also 
likely to be activated during tissue injury, which plays a role in cell damage associated 
with severe injuries which burns 
15




complement cascade: the classical pathway, the alternative pathway, and the lectin 
pathway, each pathway is activated through different mechanism, the classic pathway 
is activated by IgM or IgG antibodies that attach  to the surface of microbes, the 
alternative pathway is activated directly by microbial surface molecules that bind the 
C3 component supplement, the lectin pathway is activated by mannose-binding lectin 






Figure 4: The complement system Several mechanisms, including the classic, 
alternative, and lectin pathways, activate the complement cascade. C3a and C3b, 
which act as pro-inflammatory mediators, are the most important mediators of the 
complement system. Membrane disruption is also caused by the development of the 




Any of these paths will enable the cleavage into C3a and C3b of the complement 
portion. The C3a acts as chemo-attractant for neutrophils and C3b binds to the surface 
of the microbes to promote phagocyte detection and enable phagocytosis
16
 . 
Furthermore, C3b forms a proteolytic complex with other complementary components 
to allow C5 to be cleaved into C5a and C5b 
17
. C5a is a chemotactic driver for 
neutrophils and also affects vascular permeability at the inflammatory site. The C5b 
attaches to the microbial surface and promotes the development of the membrane 
attack complex consisting of C6, C7, C8 and C9 
18
 . Complex membrane attack 




1.1.3. Amplification of the inflammatory response 
1.1.3.1   Innate immune system 
Immune response may be split into natural and adaptive responses to tissue 
injury or infection. The primary response to tissue invasion is supported by the innate 
immune system. The phases of vasodilatation described above, increased vascular 
permeability and cellular infiltration form part of the innate immune response. 
Macrophages, dendritic cells, natural killer cells (NK) and neutrophils are the main 
cell components of the innate immune system.  Besides these cellular elements, 
circulating effectors proteins such as complement, acute-phase reactants and the 
cascade of coagulation play important roles in innate immunity 
1
. 
The extent of innate reaction is primarily determined by the production of 
cytokines and non-cytokine inflammation mediators. Cytokines are polypeptides 
formed by immune system cells in response to an infection or damage to the tissue. 
They work to control inflammatory and immune reactions. Generally speaking, 
cytokine production is self-limited although certain cytokines can remain in circulation 
for long periods of time. What's more, cytokine reactions are pleiotropic and 
repetitive. TNF- is prototypical pro-inflammatory cytokine 
19
. TNF- is mainly 
activated by macrophages within minutes of local or systemic damage, and modulates 
a number of immunological and metabolic events. TNF- initiates an inflammatory 
response at sites of local infection or inflammation, which stimulates anti-microbial 
resistance mechanisms and replaces tissue until the infection has been eradicated 
20
. It 
is a potent neutrophil and mononuclear phagocyte activator that also acts as a growth 
factor for fibroblasts and an angiogenesis factor. 
These PAF, a phospholipid autocoid produced by endothelial cells that controls 
the release of cytokines and amplifies the pro-inflammatory response, has been 
implicated in many non-cytokine inflammatory processes
21
 . The adhesion of 
neutrophils to endothelial cells seems to be an important factor. PAF's extended 
involvement in serum of SIRS patients has associated with negative outcome. 
Eicosanoids are metabolites of arachadonic acid which regulates many aspects of the 
immune response. Leukotrienes (LTC4–LTE4) allow the endothelial cells to contract 
and promote capillary leakage. Thromboxane A2, a catalyst originating from the 







1.1.3.2   Acquired immune response 
Often, the innate immune response helps to activate and enhance the immunity 
acquired. This influence is mainly mediated by IL-12, which induces T-cell activation 
and facilitates the segregation of T-cells naive into the Th1 phenotype
22
 . However, the 
adaptive immune response is mainly triggered by the introduction of foreign antigens 
to T-cells CD4 + and CD8+ T. Activation of CD4+ T-cells triggers further 
development of cytokines and amplifies the innate and acquired immune systems. At 
the time of antigen presentation, the different cytokines generated by CD4+ cells are 
dependent upon the immunological microenvironment. 
CD4 T-cells are the best-defined subsets of Th1 and Th2 cells. Those subsets are 
characterized primarily by the cytokines they generate. IFN- is the principal cytokine 
formed by Th1 cells,  In fact, IFN- amplifies the pro-inflammatory reaction by 
inducing activation of the macrophage and activating the cytolytic functions of CD8 
T-cells 
23
 . IFN- also activates B-cells to develop IgG1 and IgG3 antibodies that are 
opsonizing and complement binding 
24
 . Helminths and the susceptibility to allergens 
induce the differentiation of Th2. Such stimuli induce sustained stimulation of T-cells 
without an significant innate immune response or activation of the macrophage. 
Two more T-cell subsets are Th3 and T-regulatory 1 (Tr1) cells. Th3 cells 
produce TGF-b and play an important role in the development of immune tolerance, 
particularly after exposure to antigens supplied via the gastrointestinal tract 
25
. 
1.2. Relationship between inflammatory process and chronic 
diseases 
1.2.1. A generic model of chronic inflammatory disease 
Several diseases such as type 2 diabetes, obesity, Alzheimer’s disease, heart 
disease and allergies have few common factors; first and foremost, they are all 
primarily lifestyle diseases and are usually related to chronic inflammation. 
A generic model of chronic inflammatory disease is proposed to change the 
traditional thoughts that have claimed the chronic diseases of various organ systems as 
their own, and probed the pathophysiology in a reductionist manner, however these 
chronic diseases have more mechanisms in common than usually recognized so this 






The epithelial and mesenchymal cells of the affected organs are two prototypic 
cell types induced by signals resulting from interactions between the innate and 
adaptative immune systems (Figure 5). These signals induce tissue responses such as 
recruitment of leukocytes involved in chronic inflammation, extracellular matrix 





Figure 5: Common inflammatory and immune processes on different cell 
types.Inflammatory and immune activity alters the function of various types of 
epithelial cells such as endothelial cells, synoviocytes, enterocytes, 
glomerular/tubular epithelial cells, and bronchoalveolar cells, and each cell type 
characteristically participates in the development of a different disease 
(atherosclerosis, arthritis, inflammatory bowel disease, kidney disease, and lung 
disease, respectively). Inflammatory and immune processes may also act on different 
types of mesenchymal cells (e.g., smooth muscle cells, fibroblasts, myofibroblasts, 
mesangial cells, or pericytes), leading to the development of chronic disease 




Atherosclerosis, interstitial lung disease, rheumatoid arthritis and cirrhosis share 
the same fundamental mechanisms and mediators drive the disease process; however 
they act in totally different ways 
27,28
. In many organs, helper T-cell bound in the 
lesions of chronic inflammation including atherosclerotic plaques, forms of chronic 
hepatidites, rheumatoid synovium and in a number of pulmonary diseases. 
Mononuclear phagocyte, histocyte, microglia, or alveolar macropages are also found 
in such lesions. Every tissue involved has specific epithelial cells: the vascular 
endothelial cells in atherosclerosis; the glomerular or tubular epithelial cell in renal 
disease; and enterocytes in inflammatory bowel diseases. Similarly, depending on the 




mesenchymal cells, arterial smooth muscle cells, fibroblasts, myofibroblasts, 
synoviocytes, pericytes or mesangial cells. The first step of inflammation involves 
selective and sequential migration of blood cells into tissues and the second step is the 
local activation and interaction of these blood-based cells with resident tissue cells. 
Only some limited elements of this classic inflammatory process can be displayed by 
some conditions. However, the key inflammatory mediators dominate but without the 
context of the classic inflammatory mechanisms.  
 In osteoporosis, mediators such as IL-1, IL-6 and TNF- are primarily 
furnished by resident stromal cells to regulate bone turnover unaccompanied by other 
components of the classic innate immune response. A normal host defense mechanism 
can coax into an injurious response due to a persistent stimulus. Infection due to a 
pyogenic microbial pathogen engenders an acute leukocyte response to clear the 
invading organism. 
1.2.2. Examples of chronic diseases related with inflammation 
There are numerous chronic diseases related with inflammation (Table1). 
Nevertheless, some diseases are considered more relevant as they cause irreversible 
damage to the human organisms. 
1.2.2.1   Relationship between inflammation and atherosclerosis 
Atherosclerosis is a disease in which the inside of an artery narrows due to the 
buildup of plaque (Figure 6). In initial stages there are generally no symptoms, but in 
advanced stages, depending on the type and place of the affected arteries, it can result 
in different complication such as:  coronary artery disease, stroke, peripheral artery 







Figure 6: Figure A shows a normal artery with normal blood flow. The inset image 
shows a cross-section of a normal artery. Figure B shows an artery with plaque 
buildup. The inset image shows a cross-section of an artery with plaque buildup
28
. 
From a deep point of view, vascular endothelial cells resist to prolonged contact 
with leucocytes; however they express a palette of vascular cell adhesion molecule-1 
(VCAM-1) and members of the selectin family, P- and E-selectin, when they are 
exposed to an activating stimulus such as  modified lipoproteins, microbial 
constituents or pro-inflammatory cytokines
29
; Monocytes migrate directly into artery 
wall after adhesion to the endothelial surface; this directed migration is mediated by 
chemokines such as monocutyes chemoattractant protein-1 (MCP-1)
30
. Once resident 
in the arterial intima, these monocytes differentiate into macrophages and proliferate 
after exposition to such activating and co-mitogenic mediators as macrophage colony-
stimulating factor (M-CSF)
31
,. These  macrophages over-express scavenger receptors 
and through endocytosis they engulf modified lipoprotein particles, then they 
accumulate cholesteryl ester (CE) in cytoplasmic droplets creating foam cells, 
considered a hallmark of the nascent atherosclerotic plaque
32
. 
 The inflammatory and immune process contribute to acute thrombotic  which is 
one o the ultimate complications o atherosclerosis
30
.  Inflammation within the 
arterialintima leads to signal exchange among the T-cell, mononuclear phagocyte, and 
cells of the vessel wall. This pathway leads to a weakening of the fibrous plaque 
through decreased collagen synthesis or increased degradation. IFN- mediates 




inflammatory signaling. CD40 ligation augments the thrombogenecity of the lipid core 





Figure 7: Simplified model illustrating the effects of inflammation on the integrity 
of the plaque fibrous cap signaling between T cells, mononuclear phagocytes, and 
vessel wall cells occurs when the arterial intima is inflamed. Through decreased 
collagen synthesis or increased breakdown, this mechanism causes the fibrous 
plaque to weaken. IFN-mediates decreased synthesis while increased breakdown is 
a result of proteinases induced by inflammatory signaling. The production of tissue 
factor, a key activator of thrombus formation, is enhanced by CD40 ligation, which 




1.2.2.2 Relationship between inflammation and Alzheimer’s disease 
Alzheimer’s disease is a progressive chronic neurodegenerative disease that get 
worsens over time. This chronic disease is characterized by cognitive decline and the 




Figure 8: Comparison between healthy and Alzheimer affected brain; the neuron of 






In pathologically vulnerable regions of Alzheimer’s disease, clearly local 
peripheral inflammatory responses with full complexity were found. The inflammation 
is stimulated by degenerating tissue and deposition of highly insoluble abnormal 
materials, likewise damaged neurons, and neurites and highly insoluble 
amyloid β peptide deposits and neurofibrillary tangles provide obvious stimuli for 
inflammation. These stimuli are discrete, microlocalized, and present from early 
preclinical to terminal stages of Alzheimer’s disease that’s why local upregulation of 
complement, cytokines, acute phase reactants, and other inflammatory mediators are 
also discrete, microlocalized, and chronic. Direct and bystander damage from 
Alzheimer’s disease inflammatory mechanisms are cumulated over many years and 
are likely to significantly give rise to pathogenic processes.  Clinical studies and 
animal models strongly suggest that Alzheimer’s disease inflammation significantly 






Table 1: Examples of chronic diseases related with inflammation. 









disease that causes 
obstructed airflow 
from the lungs. 
Both innate (macrophages/neutrophils) and adaptive inflammatory 
immune cells (CD4, CD8 and B lymphocytes) which developed 
lymphoid follicles increased the tissue volume of the bronchial wall 
characterized by infiltration of the wall. 
Phosphatidylcholine 










a build-up of 
fats in the liver 
caused by drinking a 
large amount of 
alcohol. 
Expression of the following inflammatory molecules in the 
liver: tumor necrosis factor α (TNF-α), monocyte chemotactic protein 
1 (MCP-1), chemokine (C-X-C motif) ligand 1 (CXCL-1) and 





Obesity a complex 
disease involving an 
excessive amount of 
body fat. 
Abnormal cytokine production, increased synthesis of acute-
phase reactants and activation of inflammatory signaling pathways 






condition where the 
kidneys don't work 
as well as they 
Activation of the prototypical proinflammatory signaling 
pathway, the best characterized being NF-κB and AP-1, mainly based 
on the stimulation of multiple mediators, including proinflammatory 
cytokines such as interleukin-1 (IL-1) and tumour necrosis factor α 















A condition in which 
the immune system 
mistakenly attacks 
the body. 
Substitution of the AU-rich element (ARE) in the IFN- 3 'un-
translated region (called ARE-Del) with random nucleotides which 
results in a weak but chronic expression of IFN-γ. 
Nonsteroidal anti-
inflammatory drugs (NSAIDs), 
such as ibuprofen (Motrin, 







A heart attack, 
occurs when blood 
flow decreases or 
stops to a part of the 
heart, causing 
damage to the heart 
muscle. 
inhibition of the signaling pathways of nuclear transcription 
factor κB (NF-κB), p38, c-Jun NH2-terminal kinase (JNK) and 






Psoriasis A skin 
condition that causes 
red, flaky, crusty 
patches of skin 
covered with silvery 
scales. 
Heightened innate and adaptive immune activation. 
 T helper (Th)1 and Th17 cells drive pro-inflammatory 
cytokines including TNFα, interferon-γ, IL17A, and IL23 
Anti-TNFα therapy,Topical – 








1.3. Treatment of inflammatory process 
1.3.1. Corticosteroids 
Corticosteroids are a class of steroid hormones that are produced in the 
adrenal cortex of vertebrate. Two main classes of corticosteroids, namelly 
glucocorticoids and mineralo-corticoids, are involved in the regulation of 
inflammatory response. 
 This class of drugs represents a natural starting point for empirical anti-
inflammatory therapy. The most broadly active anti-
inflammatory/immunosuppressive agents in clinical use are the glucocorticoids
43
. 
Suppression of neutrophil adherence, aggregation, phagocytosis and accumulation, 
suppression of monocyte accumulation, inhibition of prostaglandin and leukotriene 
production, lympholysis, inhibition of immunoglobulin production, and impairment 
of delayed hypersensitivity are known as specific actions of corticosteroids.  
Steroids have been widely used in the treatment of idiopathic inflammatory 
diseases of the central nervous system (CNS), including lupus cerebritis and 
temporal arteritis, as also to treat multiple sclerosis. Nevertheless, there are serious 
drawbacks to clinical trials of this class of drugs in Alzheimer’s disease.  
A high doses of corticosteroids can cause toxic effects such hypertension, 
hyperglycemia, fluid retention and exacerbation of con- gestive heart failure, 
psychiatric syndromes including psychosis, mania, and depression, gastrointestinal 
ulceration or perforation, increased susceptibility to infection, osteoporosis with 
vertebral compression fractures, aseptic necrosis of bone, myopathy, truncal 
obesity, ac- celerated atherogenesis, glaucoma, adrenal suppression, and cataracts
44
.  
1.3.2. Non-steroidal Anti-Inflammatory Drugs 
These drugs are members of a drug class that reduces pain, decreases 
fever, prevents blood clots, and decreases inflammation in higher doses. 
The first line drugs for inflammatory diseases are non-steroidal anti-
inflammatory drugs such as rheumatoid arthritis and gout. Their main role is the  
inhibition of neutrophil function and prostaglandin synthesis
45
.  Non-steroidal anti-
inflammatory drugs interact primarily with pro-inflammatory cytokines interleukin 
(IL)-1a, IL1b, IL-6 and tumor necrosis factor (TNF-α)
46
. The cardinal signs of 




stimulate white cell phagocytosis and the production of inflammatory lipid 
prostaglandin E2 (PGE2). The major mechanism that leads to the success of these 
medications is their ability to interfere with the production of prostaglandin during 






Figure 9: Block of COX action by the non-steroidal anti-Inflammatory.The NSAIDs 
can block COX action and thereby prevent the formation of the COX-derived 
inflammatory mediators. 5-HPETE = 5-hydroperoxyeicosatetraenoic acid; LTC4 = 
leukotriene C4; PGE2 = prostaglandin E2; PGF2 = prostaglandin F2; PGI2 = 




Steroidal and non-steroidal anti-inflammatory medications have a significant 
side effect profiles; there is a greater interest in natural compounds, such as dietary 
















Table 2: Mechanism of action, Structure and Side effects of some steroidal and non-steroidal anti-inflammatory drugs. 




Decreases inflammation through suppression of the migration of 
polymorphonuclear leukocytes and reversing increased capillary 
permeability. It also suppresses the immune system by reducing the 




















Switching off multiple activated inflammatory genes through 
inhibition of HAT and recruitment of HDAC2 activity to the 



















The methylprednisolone-glucocorticoid receptor complex binds and 
blocks promoter sites of pro-inflammatory genes, promotes 
expression of anti-inflammatory gene products, and inhibits the 
synthesis of inflammatory cytokines, mainly by blocking the function 


































or absent menstrual 
periods 




Non-selective, reversible inhibition of the cyclooxygenase enzymes 





dizzy, feeling sick 










Blocks arachidonate binding to competitively inhibit both 
cyclooxygenase (COX) isoenzymes, COX-1 and COX-2, resulting in 







in the ears, changes 










Selective inhibition of cyclooxygenase-2 (COX-2), which is 
responsible for prostaglandin synthesis, an integral part of the pain 








swelling in the 

























Inhibition of prostaglandin synthesis by inhibiting cyclooxygenase-1 















Inhibition of prostaglandin synthesis by inhibiting cyclooxygenase-1 

















diarrhea, a feeling 
of bowel fullness, 
constipation, 











Inhibition of cyclooxygenase (COX-1 and COX-2). Piroxicam is a 
potent inhibitor of prostaglandin (PG) synthesis in vitro. 

















































Table 2 shows that corticosteroid and non-steroidal anti-inflammatory drug 
molecules contain at least one chemical group in their composition, such as hydroxyl, 
methyl, and ketone. This property will assist us in finding a natural matrix that will 
substitute these synthetic drugs with lower side effects. 
1.3.3. Natural anti-inflammatory agents 
Most anti-inflammatory medications were linked with an elevated risk of severe 
upper gastrointestinal problems. The level of risk for anti-inflammatory drugs has been 
estimated through epidemiological studies. Using oral steroids or low-dose aspirin, the 
likelihood of upper gastrointestinal tract leakage or perforation rises by almost twice 
as high as with the use of non-aspirin, non-steroidal, anti-inflammatory medicines. 
Overall, with more than one anti-inflammatory drug administered concurrently, the 
risk is dose dependent and is higher. Therefore, in order to minimize the risk of severe 
upper gastrointestinal complications, anti-inflammatory drugs should be prescribed 
during mono-therapy and at the lowest effective dose whenever possible 
3
. 
Owing to the substantial side-effect profiles of steroidal and NSAID drugs, there 
is a greater interest in natural compounds, such as nutritional supplements and herbal 
medicines, which have been used for centuries to reduce pain and inflammation. Many 
of these natural compounds often act in a similar fashion to NSAIDs by inhibiting 
inflammatory pathways. Many natural compounds function to inhibit the inflammatory 
pathways of nuclear factor-kB (NF-kB) in addition to the COX pathway 
4
. 
One of the most effective natural anti-inflammatory agents available is the 
omega-3 polyunsaturated fatty acids
58
. The American Heart Association for the 
prevention of this disease recommends the consumption of fish and fish oil 




Eicosapentaenoic (EPA) and docosahexaenoic acids (DHA) are the active 
ingredients in fish oil and can enhance the conversion of COX to prostaglandin E3 that 
is a natural anti-inflammatory agent. Prostaglandin E3 competitively inhibits the 
effects of the arachidonic acid conversion to prostaglandin E2, a highly inflammatory 
substance. It also inhibits the synthesis of TNF-α and IL-1b, both of which are 
inflammatory cytokines.  The 5-LOX pathway can be inhibited by the EPA and DHA, 
which converts arachidonic acid to inflammatory leukotrienes, by competitive 
inhibition as well
4




synovial cartilage by the direct reduce of the degenerative enzymes, aggrecanase and 
matrix metalloproteinase, as well as IL-1, TNF-α, and COX2
60
.  
One of the oldest herbal remedies for pain and inflammation is bark from the 
white willow tree, dating back to ancient Egyptian, Roman, Greek, and Indian 
civilizations, as an analgesic and antipyretic agent. White willow bark and aspirin have 
a similar mechanism of action which is the block of inflammatory prostaglandins by 
nonselective inhibitor of COX-1 and COX-2
61
. Various studies comparing white 
willow bark with non-steroidal anti-inflammatory drugs have shown an interesting 
activity, comparable to the synthetic agents. White willow bark can lead to few side 
effects because of the conversion of salicin to salicylic acid by the liver; but these side 
effects are much fewer than the ones caused by aspirin and other agents. However, it is 
costlier than aspirin, and should not be used in children, or in patients with peptic ulcer 
disease, poorly controlled diabetes, hepatic or renal disorders, or other conditions in 
which aspirin would be contraindicated
62
. 
Besides its efficacy in the prevention form cardiovascular diseases and cancer, 
green tea has been used in the treatment of arthritic disease as an anti-inflammatory 
agent. Polyphenolic compounds called catechins, and epigallocatechin-3 galate are the 
most abundant constituents of green tea. Epigallocatechin-3 galate leads to proteogly 
can release and type 2 collagen degradation in cartilage explants by the inhibition of 
IL-1
46
, it also suppresses IL-1b and attenuates activation of the transcription factor 
NF-k In human in vitro human  models. The aggrecanases which degrade cartilage 
it’s also inhibited by green tea
4
 .
In ancient civilizations, herbal practitioners relied on herbs to strengthen the 
body's immune systems. In several countries, ginger and its derivatives have improved 
the immune system. Gingerol, shogaol, and other structurally related compounds in 
ginger block biosynthesis of prostaglandin and leukotriene by blocking 5-lipoxygenase 
or prostaglandin synthetase. In addition, they can also inhibit pro-inflammatory 
cytokine synthesis such as IL-1, TNF-α, and IL-8.Studies have shown that ginger 
extract in liver cancer-induced rats has been able to suppress elevated expression of 
NFκB. Similarly, elevated expression of TNF-α was also inhibited by the treatment 
with ginger extract in liver cancer rats. It is obvious that ginger can serve as an anti-
cancer and anti-inflammatory agent by blocking NFκ activation through the 






B. dioica a perennial growing herb with tuberous roots that occurs in temperate 
Europe, North Africa, and West Asia. B. dioica aqueous extract can induce apoptosis 
in Burkitt’s lymphoma cells line BL41 by triggering the mitochondria mediated 
pathway (the disruption of mitochondria, the activation of caspase-9 and -3, the 
cleavage of PARP and degradation of PUMA). The phytochemical screening indicated 
the existence of bioactive compounds which may contribute to the B. dioica aqueous 
extract's apoptogenic function, such as flavonoids, triterpens and sterols. B. dioica may 




A lot of other plants are known for their anti-inflammatory activity, table 3 
shows the technique used, the active compound and its anti-inflammatory effect, and 
the anti-inflammatory activity which is presented by the EC50(g/mL - corresponding 
to the sample concentration giving 50% of NO production inhibition)for various 





Table3:  In vitro anti-inflammatory activity of natural matrices. 





Acacia tortilis (Forssk.) inhibition of nitric oxide (NO) 
production in a cell-based model of 
lipopolysaccharide (LPS)-stimulated 






and COX-2 enzymes that are 
involved in the inflammatory 
response. 
 
88 ± 4* 
67
 
Acanthus montanus (Nees) inhibition of nitric oxide (NO) 
production in a cell-based model of 
lipopolysaccharide (LPS)-stimulated 
RAW 264.7 murine macrophage-like 
cell line 
verbascoside - 91.50±0.95 68 
inhibition of COX-2 expression 92.55±0.64 
Aloe Vera (Carl Linnaeus) inhibition of nitric oxide (NO) 
production in a cell-based model of 
lipopolysaccharide (LPS)-stimulated 
RAW 264.7 murine macrophage-like 
cell line 
aloe-emodin active against the 
human colon cancer cell lines 
DLD-1 and HT2. 
 




(Coss. & Dur.) 
 
inhibition of nitric oxide (NO) 
production in a cell-based model of 
lipopolysaccharide (LPS)-stimulated 
RAW 264.7 murine macrophage-like 
cell line 
perilla Aldehyde and 
limonene 








inhibition of nitric oxide (NO) 















(Bercht. & J.Presl) 
inhibition of nitric oxide (NO) 
production in a cell-based model of 
lipopolysaccharide (LPS)-stimulated 
RAW 264.7 murine macrophage-like 
cell line 
- - 60 72 
Bauhinia variegate L. 
 
inhibition of nitric oxide (NO) 
production in a cell-based model of 
lipopolysaccharide (LPS)-stimulated 
RAW 264.7 murine macrophage-like 
cell line cultured in DMEM medium 













inhibition of nitric oxide (NO) 
production in a cell-based model of 
lipopolysaccharide (LPS)-stimulated 
RAW 264.7 murine macrophage-like 
cell line 
- - 39.6±6.8 74 
Brillantaisiao wariensis P. 
 
inhibition of nitric oxide (NO) 
production in a cell-based model of 
lipopolysaccharide (LPS)-stimulated 




- 71.01±0.65 68 
 inhibition of COX-2 expression   71.01±0.65  
Buddleja salviifolia (Lam) 
 
inhibition of nitric oxide (NO) 
production in a cell-based model of 
lipopolysaccharide (LPS)-stimulated 
RAW 264.7 murine macrophage-like 
cell line 
Acteoside - 42 75 
Cassia fistula L. (Collad.) inhibition of nitric oxide (NO) 
production in a cell-based model of 










lipoxygenase inhibition activity (LOX) Essential oils - 36.79 76 
Jacaranda arborea               
(Urban) 
inhibition of nitric oxide (NO) 
production in a cell-based model of 
lipopolysaccharide (LPS)-stimulated 






(jacaranone)  and its 
ethyl ester 
Inhibition of the 
production of TNF-a in LPS-
treated macrophages with 
low toxicity 
0.99 (uM) 77 
Morinda citrifolia             
(Carl Linnaeus) 
 
inhibition of nitric oxide (NO) 
production in a cell-based model of 
lipopolysaccharide (LPS)-stimulated 
RAW 264.7 murine macrophage-like 
cell line 
- - 67 75 
Nigella sativa (Mill.) inhibition of nitric oxide (NO) 
production in a cell-based model of 
lipopolysaccharide (LPS)-stimulated 








- 6.3 78 
Rauvol fiavomitoria (Afzel) inhibition of nitric oxide (NO) 
production in a cell-based model of 
lipopolysaccharide (LPS)-stimulated 
RAW 264.7 murine macrophage-like 
cell line 
 
peraksine derivatives -  
17.52 to 20.99 
79
 
Rubus rosifolius (Sm.) inhibition of nitric oxide (NO) 
production in a cell-based model of 
lipopolysaccharide (LPS)-stimulated 










As stated in Table 3, aloe-emodin, perilla aldehyde,  phenolic acids, flavonoid 
glycoside, flavan-3-ols, peraksine derivatives, methyl (1-hydroxy-4-oxocyclohexa-2,5- 
dien-1-yl), acetate (jacaranone), ethyl ester , verbascoside , artemisinin , scopoletin , 
chrysosplenetin, eupatin , sitosterol-3-O-β-d—glucopyranoside,  essential oils, trans-
sabinene hydrate, methyl-ether, 1,2-epoxy-menth-4-ene21, acteoside  terpenoids , 
alkaloids, and triterpenoids are the most important bioactive molecules  found in the 
natural matrices that have chemical features responsible for the anti-inflammatory 
properties. These molecules present in their structure chemical groups such as hydroxyl, 
methyl, and ketone, similar to the synthetic drugs and thus corroborating the efficacy of 
these functional groups in the treatment of inflammation processes. Hydroxyl and ketone 
groups are required for glucocorticoid activity in the immune system, glucocorticoids are 
part of the feedback process that decreases certain facets of immune function, such as 
inflammation. Therefore, they are used in medicine to combat conditions such as 
allergies, asthma, inflammatory diseases, and sepsis that are caused by an overactive 
immune system. 
1.4. Methods for assessing anti-inflammatory activity 
1.4.1.   In vivo assessment 
There are several in vivo anti-inflammatory methods commonly used by the 
scientific community such as: i) “Cotton Pellet Method of Meier, Schuler and 
Desaulles”, based in the fact that anti-inflammatory medication decreases the deposition 
of granulation tissue. This assay basically consists of the insertion of pellets in mice that 
are further injected with anti-inflammatory agents. Afterwards the mice are sacrificed, the 
pellets extracted, the extraneous tissue is cut off and the pellets are dried overnight. The 
pellets are measured again and the volume of granulation tissue is calculated 
80
; ii) 
“Inhibition of the Tuberculin Reaction in B.C.G.  Sensitized Guinea Pigs” method, also in 
use, is based on the findings that some fractions of liquor ice extract were as active as 
cortisone. In this assay, white guinea pigs are sensitized to tuberculin, and are 
subcutaneously injected with the anti-inflammatory agent with the aim at analyzing the 
inflammation reducing capacity 
81
, iii) “Rat Foot Test”, in which formaldehyde solution 
is injected into the right rear foot plantar aponeurosis and the degree of swelling is 
measured. The difference between the amount of the injected and the none injected foot 




percentage of the none injected foot
82
, iv) “Granuloma Pouch Method”, in which a 
volume of air is gradually inserted under the skin of the rat's back through a fine 
hypodermic needle. Anti-inflammatory medicine reduces pouch wall thickening and fluid 
exudation into the sac 
83
, v) “Topical anti-inflammatory activity” was tested in mice as an 
inhibition of the ear oedema caused by croton oil.  Croton oil suspended in aqueous 
ethanol is applied to the inner surface of the right ear. The anti-inflammatory activity was 
demonstrated as a proportion of the decrease in oedema in treated mice. Indomethacin, a 
non-steroidal anti-inflammatory drug (NSAID), was used as a guideline
84
; vi) 
“Carrageenan-induced rat paw edema assay”, uses carrageenan-induced rat paw edema. 
By subplantar injection of carrageenan (1 percent w/v), edema was briefly caused on the 
right hind paw. The amount of injected and contra lateral paws was measured after 
inflammatory activation using a plethysmometer (Orchid Scientific Laboratory). The 
value is calculated as a decrease in volume percentage compared to the control group at 
various time intervals
85
, vii) “Detection of ROS and NO production in an established 
zebrafish model; ROS is often over-released as inflammatory response happens, in 
addition to extreme NO as an indication of inflammation response. A zebrafish model is 
commonly used as a convenient and economical animal screening model to test anti-
inflammatory effects in vivo, where the output of NO and ROS is calculated 
86
. 
1.4.2.   In vitro assessment 
Regarding the in vitro assessments, there are also a wide range of assays used to 
perform a first screening to select the most promising anti-inflammatory agents.  
“PhagoBurst Assay”, consists in kits that use flow cytometry to examine the 
phagocytic activity of granulocytes and monocytes in the whole blood. Phagotest allows 
for the quantitative evaluation of leukocyte phagocytosis (bacterial uptake). It specifies 
the percentage and activity (number of bacteria per cell) of phagocytes that ingest 
fluorescein-isothiocyanate (FITC) labeled opsonized bacteria
87
. 
In the “Anti-inflammatory bioassay”, a reaction mixture consisting of egg albumin, 
phosphate buffered saline and varying concentrations of the anti-inflammatory agent is 
incubated with egg albumin under controlled experimental conditions. Then, the  
absorbance is measured and the percentage inhibition of protein denaturation is calculated 








% inhibition = 100 × [ Vt / Vc – 1] 
Where, Vt = absorbance of test sample, Vc = absorbance of control. 
The “Cyclooxygenase inhibitors”, is also anin vitro approach used for more than 
two decades and is based in the incubation of arachidonic acid with COX-1-containing 
sheep seminal vesicle microsomes. However, distilled COX-2 and COX-1 were used in 
2000 and 2004, respectively, by the same community. To identify the COX inhibitory 
effect of plant extracts, various parameters were used. To be considered active, some 
researchers set a minimum COX inhibition of 50 percent for water extracts and 70 
percent for organic solvent extracts. The standards where the inhibition was below 20 
percent were considered negligible. COX inhibition activity is known to be marginal 




About the “Lipoxygenase inhibitors”, it is interesting to point out that leukotrienes 
are another class of inflammatory mediators formed by LOX enzymes from arachidonic 
acid metabolism. It has been documented that leukotrienes are responsible for binding 
white blood cells to the endothelium of weakened blood vessels and function as 
phagocyte chemoattractant. In addition, leukotriene development has been linked to 
clinical symptoms of pathological disorders such as asthma and anaphylaxis. 
Leukotrienes, formed by 5-LOX in inflammatory cells such as poly-morphonuclear 




Finally, the “Inhibition of nitric oxide (NO)”, maybe the most used one, is based on 
the ability of anti-inflammatory agents to suppress inflammatory processes through the 
inhibition of nitric oxide (NO) production, in a cell-based model of lipopolysaccharide 
(LPS)-stimulated RAW 264.7 murine macrophage-like cell line 
67
. 
1.5. Importance of new methods/compounds for the treatment of 
these processes 
1.5.1. Targeting glycolysis with small molecules to elicit an anti-
inflammatory effect 
Several models of infection and inflammation have shown an anti-inflammatory 
response after the inhibition of hexokinase by 2-DG and GAPDH by Heptelidic acid as 






.  Targeting the glucose transporter Glut1 is one of the novels promising 




Figure 10:Targeting enzymes of glycolysis as an anti-inflammatory strategy. Glut-1 
glucose transporter-1, 2-DG 2-deoxyglucose, SLE systemic lupus erythematosus, RA 
rheumatoid arthritis, GAPDH Glyceraldehyde 3-phosphate dehydrogenase, EAE 
experimental autoimmune encephalomyelitis, AKI acute kidney injury. 
1.5.2. Modulating the Tricarboxylic acid cycle (TCA cycle) therapeutically 
to limit inflammation 
 The TCA cycle is located in the mitochondrial matrix; this cycle serves to break 
down nutrients such as glycolysis-generated pyruvate. Succinate, itaconate and citrate are 
metabolic intermediates that play an important role in inflammation (Figure 11). 
Succinate has several inflammatory process; the accumulation of succinate in LPS-
activated macrophages resulted in activation of Hif-1α, which is a key mediator in both 
innate and adaptive immune responses, subsequent upregulation of the pro-inflammatory 
cytokine IL-1β 
4
,  a synergistic effect on TLR signaling, as well as increasing the antigen 
presenting ability of dendritic cells
91
.  For example, scientists observed  a SUCNR1 
(Succinate Receptor 1)-dependent increase in the expression of IL-1β in synovial fluid 
from rheumatoid arthritis patients with high levels of succinate, providing more evidence 






Itaconate is recently described as immuno-modulatory derivative of the TCA cycle; 
it inhibits pro-inflammatory markers in classically activated macrophagesc (Figure 11). 
Mechanistically, itaconate has been shown to exert its anti-inflammatory actions through 
a broad range of mechanisms. It inhibits succinate dehydrogenase (SDH) and thereby 
block IL-1β production similar to DMM, and regulate IkBζ and IL-6 expression via the 
transcription factor ATF3
93,94
. This ability to influence key immune-modulators makes 
boosting cellular itaconate levels an attractive therapeutic. In vivo studies shows that 
itaconate is an important mediator of the resolution of inflammation, potentially 
providing a novel therapeutic opportunity and furthermore, as an endogenous metabolite 
there is strong evidence to predict good clinical tolerability 
95
.  
Citrate is another TCA cycle metabolite that accumulates in activated immune cells 
which is converted into isocitrate by aconitase enzyme (Figure 11). Activated 
macrophages and dendritic cells have an increased ratio of isocitrate to αKG and 
furthermore, reduced expression of Idh1 which, in combination with increased expression 
of the citrate carrier (CIC) and ACLY, is thought to contribute to the accumulation of the 
detected citrate
96,97
. Multiple processes play an important role in activated macrophages 
and may provide an attractive target for limiting excessive inflammation. Hence, the 









Figure 11: Modifying intermediates of the TCA cycle to drive an anti-inflammatory 
response. Enzymes include citrate synthase (CS), isocitrate dehydrogenase (IDH), 
aconitase (ACO2), α-ketoglutarate dehydrogenase (OGDH), succinyl-CoA synthestase, 
succinate dehydrogenase (SDH) which makes up Complex II of the electron transport 
chain, fumarase (FH), malate dehydrogenase (MDH) and Immuneresponsive gene-1 (IRG-
1), also known as Aconitate Decarboxylase 1 (ACOD1), the enzyme responsible for the 
production of itaconate 
95
 
1.5.3. Molecular docking; in silico study 
Molecular docking has been consistently used to highlight ligand molecules' 
molecular interactions and is thus a valuable method in the direction of drug discovery 
and development. It is one of several computational methodologies developed to help 
researchers classify candidates for new drugs and investigate them. Molecular docking 
analysis was then used to elucidate the structural criteria for interaction of compounds 
with various anti-inflammatory drug targets. 
The Research Collaboratory for Structural Bioinformatics Protein Data Bank 
(RCSB PDB, http://www.rcsb.org/pdb/home/home.do) will obtain three-dimensional 
coordinates of various inflammation-related drug targetssuch as cyclooxygenase-2, 
tumour necrosis factor-α, inducible nitric oxide synthase and galectin-3. The graphical 
user interface of the Biovia Exploration Studio Visualizer and MGLTools packages can 
be used to prepare all input files for docking. It is possible to extract native co-
crystallized ligands, water molecules and cofactors from each PDB and Gasteiger file and 




hydrogens, each rotatable bond of a ligand can be allocated. The 2D-structure can be 
transformed by the MM2 process implemented in ChemBio3D Ultra 12.0 into its 3D-
coordinate and energy reduced. For molecular docking simulation using the Lamarckian 
genetic algorithm technique, AutoDock 4.2 and AutoDock Vina 1.1 are included. The 
default docking protocol needs to be introduced with 100 individual runs for a rigid 
protein and a fluid ligand 
98
.  
Compared to the co-crystallized ones, the observed root mean square deviation 
(RMSD) of the docked ligands with minimal binding energy should be  around 2.0 Å, 
suggesting that the scoring parameters implemented in both AutoDock 4.2 and AutoDock 
Vina 1.1 are accurate 
98
. 
1.6. Cellular cycle and apoptosis 
The cell cycle is a strictly mediated mechanism responsible for sufficient cell 
division, growth, and differentiation. To ensure equal distribution of duplicated genetic 
material in the daughter cells, it combines DNA replication with chromosomal 
segregation. The phases of the cell cycle are classified into four sequential phases, which 
proceed from quiescence (phase G0) to proliferation (phases G1, S, G2, and M) and back 
to phase G0 as seen in (Figure 12). A characteristic of tumor cell growth is known to be 
the deregulation of this process. Therefore, the development of drugs targeting cell cycle 
phases has been heavily focused on both academic and commercial drug research 
projects. Researchers can easily and accurately identify various phases of the cell cycle 
using sophisticated flow cytometry
99
. A disregulation of the cell cycle components may 
lead to tumor formation; when certain genes, such as cell cycle inhibitors, RB, and p53, 
change, they might cause the cell to grow uncontrollably, resulting in the creation of a 
tumor. Although tumor cells have a cell cycle that is equivalent to or longer than normal 
cells, the proportion of cells involved in active cell division is substantially higher in 
tumors than in normal tissue. As a result, the number of cells that die through apoptosis 







Figure 12:  Inner circle: Phases of generic eukaryotic cell cycle. Outer circle: characteristic 
phenotype of budding yeast cells in distinct cell cycle phases.
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Apoptosis is a type of programmed cell death seen in multi-cellular organisms; it's 
a characteristic cell changes (morphology) and death that are the result of biochemical 
processes.  Cell shrinkage, nuclear fragmentation, chromatin condensation, chromosomal 
DNA fragmentation, and global mRNA degradation are manifestations of these 
alterations. It’s important to note that the apoptosis kills between 50 and 70 billion cells a 




The aim of this study was to characterize the bioactive compounds and bioactive 
activities of Z. officinale and B. dioica as potential natural matrice. It was also planned to 
research the health-promoting properties of its hydroethanolic extracts in order to see 
whether they could be used as functional ingredients. 
The specific objectives were: 
- Obtaining hydroethanolic extracts and assessing bioactive properties such as anti-
inflammatory activity, NOS activity, cytotoxicity in tumor and non-tumor cells, 
antioxidant activity, cell cycle analysis and apoptosis. 




3. Materials and methods 
3.1. Preparation of the samples 
The tuberculoses Z. officinale was bought at a local supermarket and B. dioca were 
collected in Bragança in late summer of 2020, Both samples used in this research were 
frozen and lyophilized. The samples after the lyophilization process are shown in Figure 
13. 
 
Figure 13: Lyophilized samples; a: Z. officinale., b: B. dioica 
 
After ensuring that both samples were fully dehydrated, they were grounded (20 
mesh) and stored at 4°C in a light-protected environment as shown in Figure 14. 
 







3.2. Preparation of the hydroethanolic extracts 
1 g of each sample was mixed with 30 ml of ethanol: water (80:20 v/v) in a 30 ml flask. 
After that, the samples were macerated for 1 hour at room temperature in a magnetic 
stirrer plate (LBX H20D Labbox, 550W, Barcelona, Spain). The samples were then 
filtered through a Whatman paper N
o
 4 filter and the ethanol was evaporated under 
reduced pressure Büchi rotary evaporator R-210, Flawil, Switzerland). The samples were 
lyophilized (47 ºC, 0.045 bar; Freezone 4.5, Labconco, Kansas City, MO, USA)once the 
ethanol was removed (Figure 15). 
 
Figure 15:  Preparation of the hydroethanolic extracts. 
3.3. Chemical characterization of the extracts 
3.3.1. Phenolic compounds 
A Dionex Ultimate 3000 UPLC instrument (Thermo Scientific, San Jose, CA, 
USA) fitted with a diode-array detector and coupled to a mass detector (LC-DAD-
ESI/MSn) was used to analyze the extracts (Figure 16). A quaternary compressor, an 
autosampler held at 5°C, a degasser, a photodiode-array detector, and an automated 
thermostatic column compartment made up the chromatographic device. Waters 
Spherisorb S3 ODS-2 C18 (3 m, 4.6 mm 150 mm, Waters, Milford, MA, USA) column 
thermostated at 35 °C was used for the chromatographic separation. (A) 0.1 percent 
formic acid in water, (B) acetonitrile were used as solvents. The elution gradient was 
isocratic: 15% for 5 minutes, 15% B to 20% B for 5 minutes, 20-25 percent B over 10 
minutes, 25-35 percent B over 10 minutes, 35-50 percent for 10 minutes, and re-




Double online detection was performed in the DAD using chosen wavelengths of 
280, 330, and 370 nm, as well as in a mass spectrometer (MS) connected to the HPLC 
device through the DAD cell outlet. The mass spectrometer, a Linear Ion Trap LTQ XL 
mass spectrometer (Thermo Finnigan, San Jose, CA, USA) fitted with an ESI source, was 
used in negative ion mode. The nitrogen sheath gas pressure was 50 psi, the spray voltage 
was 5 kV, the source temperature was 325 °C, the capillary voltage was -20 V, and the 
tube lens offset was -66 V. The entire mass spectrum was scanned, from m/z 100 to 1500. 
35 kilojoules of collision energy is included (arbitrary units). The Xcalibur® computer 
framework was used to collect data (Thermo Finnigan, San Jose, CA, USA). 
When available, the phenolic compounds were classified by comparing their 
retention times, UV-vis, and mass spectra to those of standard compounds. Otherwise, 
compounds were tentatively described by comparing the collected data to publicly 
available records. For quantitative analysis, the UV-Vis signal was used to create a 
calibration curve for each available phenolic standard (apigenin-6-C-glucoside (y = 
107,025x + 61,531, R
2
= 0.9989, LOD = 0.19 µg/mL; LOQ = 0.63 µg/mL, peak 4) and 
quercetin-3-O-glucoside (y = 34,843x − 160,173, R
2
= 0.9998, LOD = 0.21 µg/mL; LOQ 
= 0.71 µg/mL, peaks 1, 2, and 3).Quantification of the identified phenolic compounds for 
which there was no commercial norm was done using the calibration curve of another 





Figure 16: Equipment (HPLC-MS) used in the determination of the phenolic compounds. 
3.3.2. Organic acids 
The analysis of organic acids was performed according to Silva AR  et al
103
 .1 g of 
each sample was combined with 25 mL of metaphosphoric acid in a simple procedure 
(4.5 percent). The mixture was kept out of direct sunlight and macerated for 20 minutes at 




(Whatman). The organic acids were calculated using a photodiode array detector and 
ultra-fast liquid chromatography (UFLC) Shimadzu 20A sequence (Shimadzu 
Corporation, Kyoto, Japan) (PDA) (Figure 17). 
 The organic acids were separated using a SphereClone reverse phase C18 column 
(5 m, 250 mm, 4.6 mm i.d- internal diameter.) thermostated at 35°C (Phenomenex, 
Torrance, CA, USA). Using sulphuric acid (3.6 mM) and a flow rate of 0.8 mL/min, the 
elution was carried out. The chosen wavelengths for detection were 215 and 245 nm (for 
ascorbic acid). Calibration curves with established concentrations of industrial 
requirements were generated for the quantitative study, and the organic acids found in the 









The calibration curve equations and R
2
 of the found organic acids were:  
y = 1E+07x + 231891  R² = 0.9999 for oxalicacid 
y = 950041x + 6255.6  R² = 0.9999 for malicacid 
y = 1E+06x - 10277  R² = 0.9997 for citricacid 
  y = 1E+08x + 614399    R² = 0.9986 for fumaricacid 
3.4. Bioactive properties 
3.4.1. Anti-inflammatory activity 
Following the procedure described by Taofiq et al
104
, RAW 264.7 mouse macrophages 
were used to assess anti-inflammatory activity. Cell cultures was collected in European 




Collection of Authenticated Cell Culture(ECACC) and grown in DMEM medium 
supplemented with 10% heat-inactivated bovine serum and L-glutamine and held at 37°C 
with humidified air and 5% CO2. According to the Trypan Blue exclusion method, cells 
with successful growth were scraped and balanced to an experimental density of 5x10
5
 
cells/mL, with a dead cell ratio of less than 5%.Cells were spread (300 L/well) into 96-
well microplates and incubated at 37° C and 5% CO2 for 24 hours to adhere and multiply. 
After that, they were incubated for 1 hour with various extract solutions at final 
concentrations ranging from 400 to 1,56 g/mL. Afterwards, they were provided 
with lipopolysaccharides (LPS, 1 g/mL, 30 L) for 18 hours. Negative controls were 
made without the addition of LPS to see whether they could induce changes in nitric 
oxide levels at baseline (NO). Dexamethasone (50 mM) was used as a positive control. A 
Griess Reagent Kit (Promega) containing sulfanilamide, N- (1-naphthyl) ethylenediamine 
hydrochloride (NED), and nitrated solutions are used to assess the presence of nitric 
oxide. The supernatant cell solution (100 μL) was transferred to a microplate, along with 
sulfanilamide and NED solution, and mixed at room temperature for 5 to 10 minutes 
each. A reference curve for NaNO2 (100 μM at 1.6 μM, y = 0.0066x + 0.1349; R
2
 = 
0.9986) was prepared in a 96-well microplate (figure 18). The amount of nitric oxide 
released was calculated by comparing the absorbance at 540 nm in an ELX800 Biotek 
microplate reader to the calibration curve. Finally, the extract concentration needed to 
inhibit NO output by 50% (EC50, g/ml) was calculated. 
 
Figure 18: Microplate used in the anti-inflammatory activity assay. 
 
3.4.2. Cytotoxicity 
The Sulforhodamine B (SRB) assay was used to assess the cytotoxic effect of the 




tumoral cell lines; NCI-H460 (non-small cell lung cancer), MCF-7 (breast carcinoma), 
Caco(colon carcinoma) and AGS(adenocarcinoma gastric cell)were obtained from DSMZ 
- Leibniz - Institut DSMZ - Deutsche Sammlung von Mikroorganismen und Zellkulturen. 
As non-tumoral cell lines; vero (fibroblast-like from African green monkey kidney) and 
A cell culture was prepared from a freshly harvested porcine liver obtained from a local 
slaughterhouse, according to an existing protocol, for hepatotoxicity testing, and it was 
planned as PLP2 (porcine liver primary culture)
105
.The cells were incubated at 37 ° C 
with humidified air and 5% CO2 in RPMI-1640 containing heat-inactivated FBS (10%), 
glutamine (2 mM), penicillin (100 U/mL), and streptomycin (100 μg/L). Prior to the 
assays, trypsin (a proteolytic enzyme) was applied to adherent cell cultures to ensure cell 
detachment and deagglomeration. The cells were pelleted after shedding by adding RPMI 
and centrifuging (5 min, 1200 rpm), then collected and resuspended in RPMI medium. 
Each cell line was prepared in 96-well plates at the required density (1.0 x 10
4
 cells/well) 
and incubated for 24 hours to achieve cell attachment. The amounts of the extracts to be 
examined were applied and incubated for another 48 hours. After that, the cells were 
fixed with cold trichloroacetic acid (10%, 100 μL) and left to stand for 1 hour at 4 °C. 
After that, the plates were washed three times in deionized water and air dried. SRB 
solution (0.1 percent in 1% acetic acid, 100 μL) was added and incubated for 30 minutes 
at room temperature. To extract excess SRB, the plates were washed with acetic acid 
(1%) and allowed to air dry. Finally, adhered SRB was solubilized by adding tris-HCl (10 
mM, 200 μL) to a microplate reader (BiotekElx800) and reading the absorbance at 540 
nm (Figure 19).Dose-response curves were obtained for each cell line studied, and GI50 
values, corresponding to the concentration of extract that inhibited 50% of cell growth, 
were determined. Two separate tests were carried out for each compound, each in 
duplicate, with the effects expressed as mean values and standard deviation (SD). 








Figure 19; Microplate reader for the cytotoxic activity evaluation. 
 
3.4.3. iNOS activity 
During the work of this master dissertation, a new method was optimized to assess 
the anti-inflammatory activity. This method is based in the inhibition of the enzyme 
responsible for the production of nitric oxide using ab211083 NOS Activity Assay Kit     
bought from Abcam. 
NOS Reaction: 40 µL of Reaction Mix was prepared by mixing 10µL of diluted 
NOS Cofactor 1, 20µL of NOS Cofactor 2 (1X), 5µL of NOS Substrateand 5 µL of 
Nitrate Reductase, this mixture was added into standard, positive control, and samples 
well, after pipetting up and down they were Incubated at 37°C for 1 hour.  Then 95 µL of 
NOS Assay Buffer and 5 µL of Enhancer were added to standard, positive control, and 
sample well without adding them to the background control wells, all this mixture was 
pipette up and down then incubated at room temperature for 10 minutes. 
For the measurement,50 µL of Griess Reagent 1 and 50 µL of Griess Reagent 2 
were added to the standard, positive control, and sample microplate wells, without adding 
reagents 1 and 2 to the background control well. After well homogenised, the mixture 
was incubated at room temperature for 10 minutes and the absorbance was measured 
immediately (for all wells) on a microplate reader at OD 540 nm. 
Nitrite activity (pmol/min/μg or mU/mg) in the test samples was calculated 
according to the following formula:  
i                    =  
 





Where: B = Nitrite amount in sample calculated from the Standard Curve (pmol); T 
= Reaction time (minutes) – 60 minutes. C = amount of protein (μg) 
107
 . 
The calibration curve equation of the NOS was: 
Y = 0.0002 X– 0.0031and                  R² = 0.9977 
3.4.4. Cellular antioxidant activity (CAA) 
RAW264.7 cells were incubated with antioxidant compounds and AAPH, a 
compound that induces oxidative stress and promotes the production of free radicals, to 
determine intracellular ROS. As a fluorescent marker, DCFH-DA was used
108
. (DCF-DA 
is a compound that is readily oxidized by peroxide radicals in the cell medium to produce 
DCFH-DA, a fluorescent compound. When DCF-DA enters the cell, it is recognized by 
esterase enzymes, which cleave the diacetate present in the molecule. The molecule is 
oxidized by ROS, resulting in DCFH-DA, which has fluorescence. The activity of 
antioxidant compounds will prevent oxidation by lowering the antioxidant ability of free 
radicals (ROS). The antioxidant activity of the compounds studied is shown by the 
decrease in fluorescence emission as compared to control cells
109
. 
The method of Wolfe and Liu (2007) was modified, and cellular antioxidant 
analyses were performed. RAW cells were washed twice with sterile HBSS (pH 7.4) after 
reaching confluence in the culture flasks, and then isolated from the surface with 0.05 
percent trypsin-EDTA. In 96-well black background culture plates, cells were plated (3.0 
x 10
4
) in 100 μL of cell/well culture medium and incubated until confluency (24-48 h). 
To minimize any difference caused by the plate's position, the perimeter wells were left 
empty. After confluence, the growth medium was separated, and the cells were washed 
with HBSS. Then, in triplicate, 200 μL of various extract concentrations were added to 
each well with 50 μM DCFH-DA prepared in ethanol and diluted in HBSS. A negative 
control of 200 μL of DCFH-DA was introduced in triplicate as a negative control. At 
37°C, the cells were incubated for 1 hour. As a positive control, quercetin was used. The 
cells were then washed three times with HBSS to ensure that any antioxidant results seen 
later in the experiment were solely attributable to the compounds incorporated by the 
cells.  After that, 100μL of AAPH was added. Fluorescence was measured at an 
excitation wavelength of 485 nm and an emission wavelength of 538 nm. 
In terms of CAA quantification, the effectiveness of antioxidant therapies for both 




fluorescence reaction readings were used to establish curves over the course of a 40-
minute assay. Excel and Integral Calculator (https://www.integral-calculator.com/) were 
used to quantify the area under each curve. Since the DCFH-DA reaction was not 
inhibited, the highest fluorescence was seen in the control wells. 
The percent reduction (or the CAA unit) was calculated from the formula described 
by Wolfe and Liu
110
,shown below:  
                  
          
           
×100 
Three separate assays listed with mean were used to calculate the percent reduction 
in quercetin. 
 
3.4.5. Cell cycle analysis 
NCI-H460 with GI50 concentration determined from the cytotoxicity assay cells 
were seeded in 6-well plates (4x10
5
 cells/well) and incubated with the GI50 concentration 
for each sample, for 72 h. Cell cycle analysis was performed using propidium iodide (PI) 
staining and flow cytometry. This assay is established on the measurement of the DNA 
content of nuclei labeled with PI.  
Following, the cells were staining according to the protocol PI/RNASE Solution 
(Immunostep, Spain, Salamanca). Were harvested cells corresponding to 2 × 10
5
 to 1 × 
106, and centrifuged for 5 minutes at 300 g, and removed the supernatant. The cells were 
fixed and added 200 µl of 70% ethanol and left in ethanol at 4 ºC for 30 minutes. 
Following, the cells were washed once in 2 ml phosphate buffered saline (PBS) and 
centrifuged for 5 minutes at 300 g and resuspended in 500 μL of PI solution (PI/RNASE) 
and incubated in the dark at room temperature for 15 minutes. Cell cycle phase 
distribution was evaluated using Accuri C6 flow cytometer (BD Biosciences, San Jose, 
CA, USA).  
The DNA content of at least 20,000 cells was counted per sample and the 
percentage ofcells in different phases (G0/G1, S and G2/M phases) of cell cycle was 






The Fluorescein Isothiocyanate (FITC) Annexin V Apoptosis Kit (BD Biosciences, 
San Jose, CA, USA) and flow cytometry were used to detect apoptosis. The percentage of 
cells in a population that are successfully undergoing apoptosis are determined using 
FITC Annexin V staining. The NCI-H460with GI50 concentration determined from the 
cytotoxicity assay cells were washed twice in PBS and resuspended at 1 106 cells/ml in 1 
x binding buffer (10 mM Hepes/NaOH, pH 7.4, 140 mM NaCl, 2.5 mM 
CaCl2).Following that, 100 μL  of the solution (1 105 cells) was transferred to a 5 ml 
culture tube, 5 μL of FITC Annexin V (BD Biosciences, San Jose, CA, USA) and 5 
μL  of PI (BD Biosciences, San Jose, CA, USA) were introduced to each tube, and 
incubated for 15 minutes in the dark at room temperature. Finally, each tube received 400 
μL  of 1x binding buffer. The Accuri C6 flow cytometer (BD Biosciences, San Jose, CA, 
USA) was used to collect 30,000 cells, and the percentage of cell distribution was 
calculated using the Accuri C6 software (BD Biosciences, San Jose, CA, USA)
111
. 
3.5.   Statistical analysis 
Throughout this work, results are expressed as mean ± standard deviation. An analysis os 
variance (ANOVA) was used to determine the statistical difference among the samples. 
When two independent samples were analyzed, a Student's T test was used to classify 
them, placing an asterisk to discriminate between two statically different samples. When 
three independent samples were analyzed, a Tukey's test was used for classification, 
using different letters to classify statistically different samples. The equality of variance 
of the samples was confirmed using a Levene’s test. Throughout the whole work, the p-
value for all statistical classifications was set at 0.05. 
4. Results and discussion 
4.1. Chemical characterization of the extracts 
4.1.1. Phenolic compounds 
Phenolic compounds are a kind of small molecules with at least one phenol unit in 
its structure. They are classified into many subgroups based on their chemical 
compositions, including phenolic acids, flavonoids, tannins, coumarins, and others. 




anti-inflammatory, antioxidant, and anti-proliferative activities. As a result, it is 
advantageous to consume plant foods that are rich in antioxidant compounds, as these can 
reduce the prevalence of some chronic diseases, such as diabetes, cancer, and 
cardiovascular disease, by reducing oxidative stress for these reasons we determined the 
phenolic compounds profile of our both samples; Z. officinale  and B. dioica
112
.  
The phenolic compounds composition for Z. officinale is presented in Table 4, 
Figure 20 and Figure 21, where it can be seen the chromatographic characteristics of 
retention time, UV-vis maximum absorption, pseudo-molecular ion, and fragmentation 
pattern, tentative identification, and quantification (mg/g extract) of the phenolic 
compounds present in the hydroethanolic extracts of Z. officinale.  
Four compounds were tentatively identified in the sample of Z. officinale. Three O-
glycosylated isorhamnetin derivatives and one C-glycosylated derivative (aglycone 
unknown).  
Peaks 1 and 2 presented a pseudomolecular ion [M-H]
-
 at m/z 769 with a unique 
MS
2
 fragment at m/z 315 (isorhamnetin aglycone), corresponding to the loss of one 
hexosyl moiety (162 u) and two deoxyhexosyl moieties (146 u + 146 u), being tentatively 
identified as isorhamnetin-O-hexosyl-di-deoxyhexoside. Peak 3 presented a 
pseudomolecular ion [M-H]
-
 at m/z 623 with a unique MS
2
 fragment at m/z 315), 
corresponding to the loss of one hexosyl (162 u) and one deoxyhexosyl moieties (146 u), 
being tentatively identified as isorhamnetin-O-deoxyhexoside-hexoside.  
Finally, peak 4 (M-H]
-
 at m/z 723) presented the same chromatographic 
characteristics as previously described by Prakash, Baskaran &Kudachikar
113
,which led 
to the tentative identification of this peak as an unknown C-glycosil derivative. This 
compound was the major one found, with 1.33±0.04 mg/g of extract.  
The chromatogram obtained for this sample revealed the presence of more peaks. 
However, the tune method used to break the compounds, for later identification, is not the 
most appropriate and therefore did not allow the tentative identification of what we think 
are gingeriol-related compounds. These type of compounds have been extensively studied 
in this samples by other authors
114-115
, and will be properly studied when a more 
appropriate tune method is developed. 
Regarding the B. dioica sample, it was not possible to identify phenolic compounds 
in the sample. It is possible to enumerate a series of reasons for which this happened, 
among which is highlighted: i) the type of extraction used for phenolic compounds was 




to the type of compounds present in the sample; iii) the MS method was not the most 
suitable for breaking the compounds present in the sample and, consequently, their 
tentative identification; and, finally, iv) the hydroethanolic extract would need an extra 
purification step to remove proteins, sugars, and other types of cellular constituents that 
may be co-eluting with the phenolic compounds. 
Since it was not possible to repeat the extractions and/or to improve the 
chromatographic method, these steps are foreseen as future work for samples of B. 
dioica, but also for Z. officinale as its crucial to reveal the phenolic compound´s 
composition to better understand the mechanism of action of both samples and to 
correlate these compounds with the exhibited bioactivity, especially for B. dioica 
considering its important activities.  
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Table 4: Chromatographic responses, tentative identification, and quantification (mg/g extract) of 












 (m/z) Tentative identification mg/g extract 


















Unknown C-glycosil derivative 1.33±0.04 
     
Total identified phenolic compounds 2.772±0.035 
Standard calibrations curves used: apigenin-6-C-glucoside (y = 107,025x + 61,531, R
2
= 0.9989, LOD = 0.19 
µg/mL; LOQ = 0.63 µg/mL, peak 4) and quercetin-3-O-glucoside (y = 34,843x − 160,173, R
2
= 0.9998, LOD = 




Figure 21: Phenolic compound´s profile of B. dioica.
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4.1.2. Organic acids 
Organic acids play a role in a variety of essential cellular processes, such as cellular 
pH regulation and redox state regulation. As a result, it's not surprising that these 
compounds are involved in the regulation of different biochemical and physiological in 
vivo processes 
116
. For these reasons, in this work, organic acid´s composition of Z. 
officinale and B. dioica were assessed. 
Oxalic, malic, citric, and fumaric acids were detected in Z. officinale, with a total 
organic acids content of 6.67±0.03g/100g dw. Oxalic, citric, and fumaric acids were 
detected in B. dioica, with a total organic acids content of 7.4±0.2g/100g dw. as seen in 
Table 5. The major organic acid found in Z. officinale was oxalic acid, which had a 
concentration of 4.77±0.04g/100g dw. Malic acid was also present with a significant 
concentration of 1.74±0.07g/100g dw, while fumaric and citric acids had low 
concentrations of 0.10g/100g w and 0.05g/100g dw, respectively. Citric acid was the 
most abundant one in B. dioica extract, with a concentration of 4.9±0.2g/100g dw, 
followed by oxalic acid with a quite important concentration equal to 2.5±0.02g/100g dw 
and fumaric acid which was quantified only in trace amount equal 
to 0.0015±0.0001g/100g dw.. 
When comparing these findings with the literature, Aicha Jelled et al
117
 determined 
the organic acid profile of Z. officinale and discovered the same composition, but with 
different quantifications; the total organic acids was equal to 3.03±0.01g/100g dw and the 
oxalic acid was the most abundant one with a concentration equal to 1.63±0.01g/100g.It's 
possible that the concentration differences are attributable to the fact that different 
extraction methods were used.  
For B. dioica there is no available data in the literature reporting the organic acids 












Table 5: Organic acid´s composition (g/100g dw) of Z. officinale and B. dioica. 
 Z. officinale B. dioica 
Oxalic Acid 4.77±0.04* 2.5±0.02 
Malic Acid 1.74±0.07 nd 
Citric Acid  0.05±0.001* 4.9±0.2 
Fumaric Acid  0.01±0.001* 0.0015±0.0001 
Total Organic Acids 6.67±0.03* 7.4±0.2 
nd - not detected. In each row, an asterisk means statistically significant differences between the 
two samples with a p-value<0.05 
4.2. Bioactivity 
4.2.1. Anti-inflammatory activity 
In terms of anti-inflammatory properties, NO is a signaling molecule that plays a 
key role in the inflammation response
118
. Its physiological levels are essential for a 
variety of processes, including vasodilatation and neurotransmission. As a result, 
excessive NO output may be a toxic and pro-inflammatory mediator, triggering 
inflammation 
119
. As a result, NO inhibition is related to the production of anti-
inflammatory drugs.  
The capacity of hydroethanolic extracts of Z. officinale and B. dioica their 
combination to modulate the synthesis of inflammatory mediator NO in RAW 264.7 
macrophages was tested in this study, and the EC50 values (μg/mL) were determined. 
According to recent studies, Z. officinale contain gingerol, shogaol, and other structurally 
related compounds that block biosynthesis of prostaglandin and leukotriene by blocking 
5-lipoxygenase or prostaglandin synthetase, In addition, they can also inhibit pro-
inflammatory cytokine synthesis such as IL-1, TNF-α, and IL-8
63,64
. B. dioica activate the 
mitochondria-mediated cascade in Burkitt's lymphoma cells line BL41. The presence of 
bioactive compounds such as flavonoids, triterpenes, and sterols  may be the reason of the 
apoptogenic role of the B. dioica aqueous extract
65
.As anti-inflammatory responses are 
usually associated with cell proliferation, in the present dissertation, the effects of Z. 
officinale and B. dioica, extracts and their combination on the proliferation of RAW 
264.7 cells were achieved.  
As shown in the Table 6 and Figure 22, the different extracts suppressed the 




B. dioica extracts presented the lowest EC50 value equal to 1.187±0.18μg/mL, which 
prove the high anti-inflammatory potential comparing to Z. officinale and their 
combination, it also shows an EC50 value even lower than the positive control 
(dexamethasone: EC50 equal to 1.6 μg/mL). Z. officinale showed a value equal to 
2.806±0.28μg/mL, while the combination of the 2 samples showed a value equal to 
2.556±0.33μg/mL. The mixture of the two extracts did not increase the anti-inflammatory 
activity, thus for the further assays the samples were analyzed separately, since no 
synergism was verified, and no additional benefit was obtained by mixing the two 
samples. 
A recent research used various in vitro and in vivo approaches to test the anti-
inflammatory capacity of Z. officinale and found that the extract has important anti-
inflammatory properties through inhibiting macrophage and neutrophil activation, as well 
as monocyte and leukocyte migration. The decline in pro-inflammatory cytokines and 
chemokines, as well as the replenishment of total antioxidant ability, corroborates that
120
. 
Once again, to the best of the authors knowledge, there are no reports on this 
subjected about B. dioica.  
Table 6: Anti-inflammatory activities of the Z. officinale and B. dioica, and their 
combination. 
Anti-inflammatory activity(EC50; μg/mL) 








EC50 values correspond to the extract concentration achieving 50% of the inhibition of NO-
production. EC50 values for dexamethasone (positive control): 1.6 μg/mL.In each row, different letters 






Figure 22:Anti-inflammatory activities of the Z. officinale and B. dioica, and their 
combination. 
4.2.2. Cytotoxic activity 
The cytotoxic activity of the hydroethanolic extracts was tested against four human 
cancer cell lines: NCI-H460 (non-small cell lung cancer), MCF-7 (breast carcinoma), 
Caco2 (colon carcinoma), AGS (adenocarcinoma gastric cell); and two non-tumor cell 
lines: PLP2 (porcine liver primary cell line) and Vero (fibroblast-like from African green 
monkey kidney). Ellipticine was used a positive control. 
The hydroethanolic extracts of Z. officinale and B. dioica were active against the 
different cell lines, as seen in Table 7. It is possible to note that Z. officinale has a much 
higher GI50 than B. dioica and ellipticine for all cell types, meaning that it has a lower 
cytotoxicity effect. Z. officinale has the highest cytotoxic activity against NCI H460 with 
the lowest GI50 value of 29.28±1.78 μg/mL, followed by Caco2 with GI50 equal 
to55.23±4.43 μg/mL, MCF-7 with GI50 of 60.71±3.26 μg/mL, and AGS with GI50 of 
90.26±7.81μg/mL.  The cytotoxic activity of Z. officinalis PLP2 is the lowest, with a GI50 
value of 133.4±3.9 μg/mL. Regarding the activity exhibited for the non-tumor cells PLP2 
and Vero, it was observed that besides the samples presents some cytotoxic effects on 
these cells, the concentration needed to cause toxicity is much higher than the one needed 




A similar research was carried out by Kottarapat et al
121
, but this time with Ginger 
essential oil (GEO). The authors found that both Lymphoma Ascites (DLA) and Ehrlich 
Ascites Carcinoma (EAC) cell lines demonstrated were strongly inhibited when exposed 
toGEO. The concentration of ginger essential oil needed to kill 50% of DLA cell lines 
(IC 50) was found to be 11 μg/mL for DLA cell line and 18 μg/mL for EAC cell line 
respectively. The differences in these findings are due to the different types of extract 
used and the different types of cells used. 
The analysis of B. dioica data revealed that MCF-7 and NCI H460 have a very 
similar GI50 values equal to 0.121±0.004 and 0.135±0.003 μg/mL, respectively, 
consecutively followed by Caco2 which has a GI50 value of 0.43±0.05 μg/mL. The GI50 
of the positive control ellipticine was higher than that of B. dioica for these three cancer 
cell lines, indicating that B. dioica is more active against these cell lines. The GI50 for 
AGS was 1.35±0.04 g/mL for B. dioica, which is slightly higher than it was for 
ellipticine, indicating that ellipticine is more effective against the AGS cell line. PLP2 
findings indicate that B. dioica was more active against cancer cell lines than normal cell 
line, with a GI50 value 4.3±0.2 μg/mL, which is a positive signal since it is possible to 
inhibit cancer cell lines without harming normal cell line simply by lowering the 
concentration below 4.3±0.2 μg/mL. Ellipticine was more active against the PLP2 cell 
line than B. dioica, making it more difficult to regulate their cytotoxicity against normal 
cell lines, being more dangerous. 
No similar study was performed to evaluate the cytotoxic activity of B. dioica, once 










Table 7: Cytotoxic activities (GI50; μg/mL) of Z. officinale and B. dioica. 
 Z. officinale B. dioica Ellipticine 
NCI H460 (non-small cell lung cancer 
cell line) 
29.28±1.78 0.135±0.003* 1.01 ± 0.01 
MCF-7 (breast carcinoma cell line) 60.71±3.26 0.121±0.004* 1.02 ± 0.02 
Caco2 (colon carcinomacell line) 55.23±4.43 0.43±0.05* 1.21± 0.02 
AGS (adeno-carcinoma gastric cell 
line) 
90.26±7.81 1.35±0.04* 1.23 ± 0.03 
PLP2 (Porcine liver primary cell line) 133.4±3.9 4.3±0.2* 1.4 ± 0.1 
Vero (fibroblast-like from African 
green monkey kidney cell line) 
196.3±11.8 2.1±0.2* 1.41±0.06 
GI50 (µg/mL) values, corresponding to the concentration of extract that inhibited 50% of cell growth. nd - 
not detected. In each row, an asterisk means statistically significant differences between the two samples 
with a p-value<0.05 
 
The analysis of (Figure 23)(A) shows that for Vero, the percentage of inhibition 
remains at 100% even though the concentration of Z. officinale is increased, then drops 
suddenly to 0% when the concentration reaches 10
-4.5
 log (concentration, µg/ml), and for 
all the other cell lines the percentage of inhibition decreases as the concentration of        
Z. officinale increases. For B .dioica (B) all the cell line shows the same graph in which 
the percentage of inhibition decreases as the concentration of the extract increases with 
the exception of PLP2 cell line in which the percentage of inhibition remains at 100% 
then drops to 0% when the concentration of the extract reaches 10
-4
 log (concentration, 









Figure 23: Dose-response curve for Z. officinale  (A)and B. dioica (B) hydroethanolic 
extract. 
 
4.2.3. iNOS activity 
NO is a signalling molecule that plays an important role in inflammatory 
pathogenesis. Under normal physiological conditions, it has an anti-inflammatory effect. 
NO, on the other hand, is a pro-inflammatory mediator that causes inflammation when 
produced in excess in irregular circumstances. Both Z. officinale and B. dioica have anti-
inflammatory properties, but we need to know at what concentrations they prevent the 






Table 8 indicates that Z. officinale has a higher IC50 value (equal to 
101.68±7.59μg/mL)than B. dioica (IC50 equal to 42.17±0.55μg/mL), assuming that 
B.dioica has a higher NOS activity and inhibits the synthesis of nitric oxide more 
efficiently. 
A study made by Nobuko Imanishiat al
122
showed that Z. offifinale has the ability to 
cause the expression of macNOS mRNA and NO development by itself. According to the 
findings of the dose-dependent assay, 100 µg/ml of Z. offifinale was necessary for 
induction (the inducible effects of 10 μg/ml and 1 μg/ml were small and negligible, 
respectively). Once again, no studies were found in the literature to evaluate the NOS 
activity of B. dioica. 
 
Table 8: iNOS activity (IC50; μg/mL) of  Z. officinale and B. dioica. 
 Z. officinale  B. dioica 
iNOS activity 101.68±7.59 42.17±0.55* 
IC50 (µg/mL) values, corresponding to the concentration of extract that inhibited 50% of iNOS activity.In 
each row, an asterisk means statistically significant differences between the two samples with a p-
value<0.05 
 
4.2.4. Cellular antioxidant activity (CAA) 
The antioxidant activity of Z. officinale and B. dioica was measured using a cellular 
antioxidant activity (CAA) assay since this test is biologically relevant when compared to 
the common chemical antioxidant activity analysis, as it covers some aspects of cell 
consumption, metabolism, and location of antioxidant compounds. 
Table 9 indicates that Z. officinale has a low percentage of oxidation inhibition at 
the maximum concentration of 1000 µg/mL equal to 27±3% indicating that we can’t 
calculate the IC50 values since this percentage did not rich 50%. B. dioica has a high 
percentage of oxidation inhibition at the maximum concentration of 1000 µg/mL equal to 
85±4 % so we can say that it has a good antioxidant activity .When compared to quercetin 
(positive control), both samples have a lower efficiency, which is attributed to the fact 
that quercetin is a synthetic and pure compound, whereas these samples are mixtures of 
molecules that may not always have a synergistic effect or a high bioactivity. B. dioica 




findings show that Quercetin has the highest antioxidant activity, followed by B. dioica 
and Z. officinale. 
Other in vivo study performed by Qian-Qian Mao et al123evaluated the antioxidant 
activity of Z. officinale using C57BL6/J mice with50 mg/mL dose. The authors found that 
the extract of Z. officinale has a strong antioxidant activity and induce the inhibition of 
TNF-α production, Akt activation, and NF-κB activation. 
Until now no study has been performed to evaluate the antioxidant activity of B. 
dioica. 
Table 9: Cellular antioxidant activity of  Z. officinale and  B. dioica 
 Z. officinale B. dioica 
% oxidation inhibition at the 
maximum concentration of 1000 
µg/Ml 
27±3 85±4* 
IC50 value (µg/mL) >1000 654±18*1 
Quercetin (positive control): % oxidation inhibition at 0,3 ug/ml inhibits 95 %; GI50 = 0.08µg/mL.nd - not 
detected. In each row, an asterisk means statistically significant differences between the two samples with a 
p-value<0.05 
 
4.2.5. Cell cycle Analysis 
Cell cycle analysis is a very common flow cytometry application.  A DNA profile 
can be determined using a DNA-specific stain, such as finding the percentage of the 
population in G0/G1, S, and G2/M. This data may be used to monitor the effectiveness of 
an anticancer drug, for example. 
 The comparison of the results of Z. officinale and the control test (cells without 
treatment) as seen in table 10 shows that there is a slight difference in the G0/G1 phase 
(60.3% for Z. officinale vs 53.1% for control test ) and in S phase (7.7% for Z. officinale 
vs 8.7% for control test).This difference is not significant, the G2 phase is the same for 
both (20.1%), thus, Z. officinale don’t have a significant effect on all the phases of the 
cell cycle. The analysis of B. dioica data shows that there is no significant difference 
between the S and G2 phases as compared to the control test 9.6 % vs 8.7 % for S and 
21.9 % vs 20.1 % for G2 for B. dioica and control test consecutively. The percentage of 
the cells in G0/G1 phase for B. dioica was lower than it was in thecontrol test 22.4% vs 





According to the published literature, no research has been done to examine if Z. 
officinale or B. dioica interfere with the cell cycle, hence this approach is important and 
usefull. 
Table 10: Cell cycle analysis of Z. officinale, B. dioica and control test 
Sample control test Z. officinale B. dioica  
G0/G1 (%) 53.1 60.3 22.4 
S (%) 8.7 7.7 9.6 
G2 (%) 20.1 20.1 21.9 
 
Figure  24 confirms that the cell cycle profiles of Z. officinale (b) and control test 
(a) are likely the same, but there is a significant difference between them and B. dioica 
(c) in the G0/G1 phase, demonstrating that B. dioica has a G0/G1 phase suppressing 
effect as discussed previously. 
 
Figure 24: Cell cycle profile of the different samples: (a) control test, (b) Z. officinale 








Flow cytometry is an important technique for detecting and quantifying the level of 
apoptosis in a population of cells at static points or over time. The apoptotic effect of               
Z. officinale and B. dioica was studied as seen in Table 11 to better understand the 
mechanism of action of both samples. 
The analysis of Z. officinale results shows that it has a lower percentage of living 
cells than the control test, 46.1% vs 63.6% but the percentage of apoptotic and dead cells 
was higher in Z. officinale than it was in living cells; 7.1% vs 6.6% for apoptotic cells and 
39.3% vs 26.2% for dead cells respectively, suggesting that Z. officinale causes the death 
of the cells by apoptosis. 
These results are conform with the study of Jennifer M. Rhode et al. 
124
. These 
authors studied the effect of Z. officinale on the ovarian cancer cells and they found that it 
causes cell death in ovarian cancer cells via apoptosis properties through p53 pathway as 
well as autophagy induction. 
The comparison of B. dioica to the control test shows that there is no significant 
difference; for live cells, B. dioica has 66.4 %, while the Blanc has 63.6 %.For apoptotic 
cells, B. dioica has 6.8 %, while the control test has 6.6 %and for dead cells, B. dioica has 
22.8 % vs 26.2 % for B. dioica   and the control test, respectively. 
The apoptotic effect of B. dioica not evaluated yet by other published studies. 
 
Table 11: Apoptotic effect of Z. officinale , B. dioica, and control test 
Samples  control test Z. officinale B. dioica 
Live cells (%) 63.6 46.1 66.4 
Apoptoticcells (%) 6.6 7.1 6.8 
Deadcells (%) 26.2 39.3 22.8 
 
Figure 25 shows that the apoptotic profiles of B. dioica (c) and control test (a) are 
most definitely the same, although there is a substantial variation between them and (b), 







Figure 25: Apoptotic effect of (a) control test, (b) Z. officinale, (c) B. dioica.





Inflammation is a protective mechanism intended to remove bacteria or irritants to 
protect living tissues from infection and damage, and to potentiate tissue repair. 
Inflammatory processes have a direct relationship with serious diseases such as 
atherosclerosis and Alzheimer’s disease.  
Different types of synthetic substances are used in the treatment of inflammation 
but unfortunately, they have side effects; that’s why there is a crucial need to find natural 
alternatives with higher efficiency and lower side effects.  Some natural substances have 
already been used, such as Omega-3 EFAs (fish oil), white willow bark, green tea among 
others, thus, there is a crucial need to develop new strategies to evaluate the activity of 
these natural substances.  
The research study presented focused on evaluating the chemical characterization 
and bioactive properties of B. dioica and Z. officinale, two plants noted for their potential 
anti-inflammatory properties. 
Both samples have revealed the presence of organic acids; however, B. dioica has a 
higher overall organic acids quantity than Z. officinale. B. dioica contained oxalic, citric, 
and fumaric acids, with citric acid being the most abundant. Z. officinale contained 
oxalic, malic, citric, and fumaric acids, with oxalic acid being the most abundant. All 
these organic acids are known for their potential importance in a lot of physiological 
process.  
Four phenolic compounds were found in the analysis of Z. officinale composition, 
nevertheless it was not possible to identify the compounds present in B. dioica until this 
moment, being this analysis ongoing.  
The anti-inflammatory results indicate that both samples and their 
combination have interesting anti-inflammatory activity, yet B. dioica has the most 
impressive findings because its EC50 value is lower than that of dexamethasone, which is 
used to treat a variety of anti-inflammatory diseases, so this discovery may have a major 
impact on the pharmacology field. 
The cytotoxic activity assay revealed that both samples were less active against 
normal cell lines than cancer cell lines; this property is critical because it allows targeting 
cancer cell lines while avoiding harming normal cell lines simply by lowering the 
samples concentration. Z. officinale had a strong cytotoxic effect, and it was particularly 




much higher than that of ellipticine (a drug used to treat a variety of tumors) and it was 
more potent against MCF-7 and NCI-H460. 
The iNOS activity results show that B. dioica has a higher iNos activity than            
Z. officinale, indicating that it reduces nitric oxide synthesis more effectively. 
The CAA data revealed that B. dioica has a higher percentage of oxidation 
inhibition and antioxidant activity (lowest GI50) than Z. officinale. However, their activity 
was lower than quercetin, a positive control and known for its potential antioxidant 
activity.  
Only B. dioica interferes with the cell cycle by suppressing the G0/G1 process, 
according to cell cycle experiment.  
The apoptosis analysis reveals that only Z. officinale causes cell death by apoptosis. 
The findings are fascinating and have the potential to benefit a variety of fields, 
including pharmacology, industry, chemistry, food, and so on. 
Z. officinale has been used as a potential plant in multiple fields, but B. dioica is a 
new finding in this study that needs to be more exploited. 
After this work's examination, four fundamental perspectives will be established:              
i) complete the chemical characterization of both samples, ii) examinate the anti-
inflammatory activity using other methods and optimize them, iii) Repeat all these tests 
in vivo to corroborate the in vitro data and to ensure their safety,iv)manufacturing of a 
topical cream containing B. dioica and Z. officinale extracts that may be applied directly 
to the site of inflammation. 
Overall, both samples revealed their promising anti-inflammatory potential. Is also 
relevant to state that these studies were the first reports on the chemical characterization 
and bioactive properties of B. dioica, since there are no reports on the literature 
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